Treatments for Alzheimer's disease emerge
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Anti-amyloid immunotherapies will provide the first disease-modifying therapeutics
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The recent approval by the US Federal Drug Administration (FDA) of a disease‐modifying drug, aducanumab 151 , has been seen as a major milestone 152 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [152]
In the citing paper
“Aducanumab may be the first of several disease‐modifying drugs coming to the clinic, and has generated renewed interest in drug treatment of Alzheimer's disease and other dementias.”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [152]
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [104]
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Self-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Cited by
Items 101–117 of 117
Systemic administration of PD-L1 blocking antibodies leads to removal of senescent microgliaPreprint
Androsova, Y., Kertser, A., Partney, H., Nathansohn, B., Ibraheem, A., Abellanas, M. A., Croese, T., Salame, T. M., Akiva, H., Krizhanovsky, V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.22.695923 · Cited by 1
Wang, R., & Lahiri, D. K. (2021) · Research Square · doi:10.21203/rs.3.rs-874750/v1
Stein, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00209-0
Kumari, P., Sarwa, N., & Chaudhary, N. S. (2025) · Current Enzyme Inhibition · doi:10.2174/0115734080356410250407092844
Ackley, S. F., Flanders, M., Murchland, A. R., Chen, R., Wang, J., Shah, S. J., Huey, E. D., & Glymour, M. M. (2025) · medRxiv · doi:10.1101/2025.07.21.25331942
“While some argue that the trial results for recent agents clearly demonstrate a causal role of amyloid in cognitive and functional decline (4,5), others speculate about the likelihood of non-amyloid mechanisms.”
Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., Kataoka, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565342
Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., Kataoka, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565345
Amano, A., Sanjo, N., Araki, W., Anraku, Y., Nakakido, M., Matsubara, E., Tomiyama, T., Nagata, T., Tsumoto, K., Kataoka, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26565348
Sanotra, M. R., Kao, S.-H., Lee, C.-K., Hsu, C.-H., Huang, W.-C., Chang, T.-C., 涂芳瑜, Hsu, I.-U., & Lin, Y.-F. (2023) · Figshare · doi:10.6084/m9.figshare.23564775
Alzheimer’s disease : epistemology, ethics, innovation
Daly, T. P. (2021) · theses.fr (ABES) · doi:10.70675/6e99838az7dd4z402fz98fdzeca072d3ad13 · Cited by 2
Im Windschatten von Amyloid: die Tau-und-Tangle-Hypothese
Behl, C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72210-7_12
Hernández, E. R., Netzahualcoyotzi, C., Hurtado‐Alvarado, G., Sánchez, J. L., Pereyra, A., Zamarripa, D. A., Hernández-Zimbrón, L. F., Papy-García, D., Guevara, J., Ponce, N. G., et al. (2026) · Brain Sciences · doi:10.3390/brainsci16050465
“…histopathological markers that can be observed by microscopy: (1) extracellular neuritic plaques (NPs) formed by the aggregation of amyloid-β (A β ) peptide; (2) the formation of neurofibrillary tangles (NFTs) that are the product of hyperphosphorylation and aggregation of the Tau protein [7,8].”
Yang, X., Gao, Y., Zhang, M., Pan, J., Liu, H., & Fan, H. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261450636
“11 However, available treatments can only slow disease progression and do not offer a cure, including speci fi c therapies targeting A β and tau proteins.”
Adisa, A. R., Martins, R. N., Krishnamoorthy, R., Alshuniaber, M. A., Bharadwaj, P., Li, Z., Coorey, R., Jayasena, V., Johnson, S. K., & Fernando, W. M. A. D. B. (2026) · Nutrients · doi:10.3390/nu18132121
“Excessive generation of A β and the accumulation of soluble A β 42 oligomers are widely recognised as critical drivers of AD onset and progression [28].”
The evolutionary origins of dementia
Stone, J. A., Johnstone, D. M., Mason, R. S., Mitrofanis, J., & Robinson, S. R. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261470053
Bhattacharya, H., Chakraborty, P., & Dewanjee, S. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.022
BindingDB Entry 50020469: Superiority of the Triple-Acting 5-HT
BindingDB (2024) · UC San Diego · doi:10.7270/q25q51hf
Metadata
- Authors
- Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Selkoe, Dennis J.
- ORCID
- Selkoe, Dennis J.
- Venue
- Science
- Published
- 2021-08-06
- Volume
- 373
- Issue
- 6555
- Pages
- 624-626
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3193092593
- Cited by
- 117
- References
- 15
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 20 · 2023: 31 · 2022: 40 · 2021: 6
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, anti-amyloid immunotherapy, disease-modifying therapy, amyloid-beta, treatment development
- MeSH terms
- Alzheimer Disease, Animals, Brain, Clinical Trials as Topic, Enzyme Inhibitors, Humans, Immunotherapy, Biomarkers, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Mice, Amyloid Precursor Protein Secretases, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.